SeaStar Medical (NASDAQ:ICU) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of SeaStar Medical (NASDAQ:ICU) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Maxim Group set a $8.00 price objective on shares of SeaStar Medical and gave the stock a “buy” rating in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.00.

SeaStar Medical Price Performance

SeaStar Medical stock opened at $3.18 on Friday. The firm has a 50-day moving average of $3.66 and a 200-day moving average of $3.41. SeaStar Medical has a one year low of $2.07 and a one year high of $12.50. The company has a market cap of $14.01 million, a price-to-earnings ratio of -0.81 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.06. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.The firm had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.49 million. As a group, sell-side analysts expect that SeaStar Medical will post -3.58 earnings per share for the current year.

Institutional Trading of SeaStar Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in SeaStar Medical in the 4th quarter valued at about $30,000. Millennium Management LLC bought a new position in SeaStar Medical in the 3rd quarter valued at about $102,000. Finally, XTX Topco Ltd lifted its position in SeaStar Medical by 395.4% during the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after acquiring an additional 48,674 shares during the last quarter. Institutional investors own 1.69% of the company’s stock.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.